Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine

NCT00058799 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

BIOLOGICAL: Dose Level 1
BIOLOGICAL: Dose Level 2
BIOLOGICAL: Dose Level 3

Sponsor

Baylor College of Medicine

Collaborators

[object Object]
[object Object]